AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyNot reportedPublished in a peer-reviewed journal
Neurologist Decisions on Disease-Modifying Treatment for Simulated RIS Cases
In a study involving 116 neurologists reviewing a simulated case of a 24-year-old woman with radiologically isolated syndrome (RIS), 58.6% chose not to recommend initiating disease-modifying treatment (DMT).
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
This study provides insights into how neurologists respond to biomarker data (sNfL) when considering treatment options for RIS, potentially impacting patient care strategies in the future.
What this does not prove
The study used simulated cases, which may not accurately reflect real clinical decision-making processes.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2025-12-22
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- 24-year-old woman diagnosed with radiologically isolated syndrome (RIS)
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- serum neurofilament light chain (sNfL) levels
- Safety
- Not reported
Original sources
- Primary evidenceAttitudes of Neurologists Toward the Potential Role of Serum Neurofilament Light Chain Measurement in Treatment Decision-Making for People With Radiologically Isolated Syndrome. ↗DOI: 10.7224/1537-2073.2025-001
Supporting passages (10)
sample size basisRESULTS: A total of 116 neurologists participated in the study (mean age, 41.9 years; 53.4% men).
interventionThis study aimed to assess how sNfL testing influences neurologists' decisions regarding disease-modifying treatment (DMT) in the management of RIS.
primary endpointThis study aimed to assess how sNfL testing influences neurologists' decisions regarding disease-modifying treatment (DMT) in the management of RIS.
findingsOverall, 58.6% (n = 68) opted against recommending the initiation of DMT.
populationParticipants reviewed a simulated case of a 24-year-old woman diagnosed with RIS, characterized by a brain MRI showing 1 juxtacortical and 8 periventricular T2 hyperintense lesions, cerebrospinal fluid oligoclonal bands, and sNfL levels of 24 pg/mL.
biomarkersBACKGROUND: Serum neurofilament light chain (sNfL) levels reflect neuroaxonal damage and independently predict conversion to multiple sclerosis (MS) in individuals with radiologically isolated syndrome (RIS).
publication datePublication date: 2025-12-22
limitationsTitle: Attitudes of Neurologists Toward the Potential Role of Serum Neurofilament Light Chain Measurement in Treatment Decision-Making for People With Radiologically Isolated Syndrome.
peer reviewedPublication types: Journal Article
subjectsTitle: Attitudes of Neurologists Toward the Potential Role of Serum Neurofilament Light Chain Measurement in Treatment Decision-Making for People With Radiologically Isolated Syndrome.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.